The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
Open accessAbstract
BACKGROUND & AIMS Inhibitors of Janus kinases (JAKs) are being developed for treatment of inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective in treatment of ulcerative colitis, but there are safety concerns. We performed a systematic review and meta-analysis to investigate the safety profile of tofacitinib, upadacitinib, filgotinib, and baricitinib in patients with rheumatoid arthritis, inflammatory bowel diseases, psoriasis, or ankylosing spondylitis. METHODS We searched the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials from January 1, 1990 through July 1, 2019. We performed a manual review of conference databases from 2012 through 2018. The primary outcome was incidence rates of adverse events (AEs) and serious AEs. We also estimated incidence rates of serious infections, herpes zoster infection, non-melanoma skin cancer, other malignancies, major cardiovascular events, venous thromboembolism, and mortality. We performed a meta-analysis, which included controlled studies, to assess the relative risk of these events. RESULTS We identified 973 studies; of these 82 were included in the final analysis, comprising 66159 patients with immune-mediated diseases who were exposed to a JAK inhibitor. Two-thirds of the included studies were randomized controlled trials. The incidence rate of AEs was 42.65 per 100 person-years and of and serious AEs was 9.88 per 100 person-years. Incidence rates of serious infections, herpes zoster infection, malignancy, and major cardiovascular events were 2.81 per 100 person-years, 2.67 per 100 person-years, 0.89 per 100 person-years, and 0.48 per 100 person-years, respectively. Mortality was not increased in patients treated with JAK inhibitors compared to patients given placebo or active comparator (relative risk 0.72; 95% CI, 0.40-1.28). The meta-analysis showed a significant increase in risk of herpes zoster infection among patients who received JAK inhibitors (relative risk 1.57; 95% CI, 1.04-2.37). CONCLUSIONS In a systematic review and meta-analysis, we found an increased risk of herpes zoster infection among patients with immune-mediated diseases treated with JAK inhibitors. All other AEs were not increased among patients treated with JAK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J.-F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32126-2 · Cited by 3,531
Self-citationFord Alexander, C., Paul, M., Hanauer Steven, B., 谭蓓, & Dong, W. Z. (2001) · Cited by 3,020
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Self-citationTofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606910 · Cited by 1,770
Self-citationPlacebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Burmester, G. R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61424-x · Cited by 714
Tofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., Cardiel, M. H., Cohen, S., Nash, P., Song, Y., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37816 · Cited by 577
Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Fleischmann, R., Mysler, E., Hall, S., Kivitz, A. J., Moots, R. J., Luo, Z., DeMasi, R., Soma, K., Zhang, R., Takiya, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31618-5 · Cited by 499
Kremer, J., Li, Z.-G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., Isaacs, J. D., Gruben, D., Wallenstein, G., Krishnaswami, S., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00006 · Cited by 448
Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32537-5 · Cited by 439
Fleischmann, R., Schiff, M., van der Heijde, D., Ramos‐Remus, C., Spindler, A., Stanislav, M., Zerbini, C. A. F., Gurbuz, S., Dickson, C., de Bono, S., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39953 · Cited by 427
Genovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.-E. F., Meerwein, S., & Pangan, A. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31116-4 · Cited by 422
Bachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
Dougados, M., van der Heijde, D., Chen, Y.-C., Greenwald, M., Drescher, E., Liu, J., Beattie, S., Witt, S., de la Torre, I., Gaich, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 404
Smolen, J. S., Pangan, A. L., Emery, P., Rigby, W., Tanaka, Y., Vargas, J. I., Zhang, Y., Damjanov, N., Friedman, A., Othman, A. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30419-2 · Cited by 379
Fleischmann, R., Cutolo, M., Genovese, M. C., Lee, E. B., Kanik, K. S., Sadis, S., Connell, C. A., Gruben, D., Krishnaswami, S., Wallenstein, G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33383 · Cited by 376
van der Heijde, D., Deodhar, A., Wei, J. C., Drescher, E., Fleishaker, D., Hendrikx, T., Li, D., Menon, S., & Kanik, K. S. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210322 · Cited by 376
Panés, J., Sandborn, W. J., Schreiber, S., Sands, B. E., Vermeire, S., D'Haens, G., Panaccione, R., Higgins, P. D. R., Colombel, J.-F., Feagan, B. G., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312735 · Cited by 373
Burmester, G. R., Kremer, J. M., Van den Bosch, F., Kivitz, A., Bessette, L., Li, Y., Zhou, Y., Othman, A. A., Pangan, A. L., & Camp, H. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31115-2 · Cited by 373
Baker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Kremer, J. M., Cohen, S., Wilkinson, B. E., Connell, C. A., French, J. L., Gomez‐Reino, J., Gruben, D., Kanik, K. S., Krishnaswami, S., Pascual‐Ramos, V., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33419 · Cited by 344
Biologic agents for IBD: practical insights
Danese, S., Vuitton, L., & Peyrin-Biroulet, L. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.135 · Cited by 342
Self-citationPapp, K. A., Menter, A., Strober, B., Langley, R. G., Buonanno, M., Wolk, R., Gupta, P., Krishnaswami, S., Tan, H., & Harness, J. A. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11168.x · Cited by 338
Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 327
Genovese, M. C., Kalunian, K., Gottenberg, J.-E., Mozaffarian, N., Bartok, B., Matzkies, F., Gao, J., Guo, Y., Tasset, C., Sundy, J. S., et al. (2019) · JAMA · doi:10.1001/jama.2019.9055 · Cited by 327
Wollenhaupt, J., Lee, E.-B., Curtis, J. R., Silverfield, J., Terry, K., Soma, K., Mojcik, C., DeMasi, R., Strengholt, S., Kwok, K., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1866-2 · Cited by 320
Wollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Wang, W., Niezychowski, W., Vermeire, S. A. R. A., Dewit, O., Peeters, H., Stehlik, J., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.029 · Cited by 300
Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S., Zwillich, S. H., & Tofacitinib Study Investigators (2011) · Arthritis Care & Research · doi:10.1002/acr.20494 · Cited by 297
Curtis, J. R., Xie, F., Yun, H., Bernatsky, S., & Winthrop, K. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209131 · Cited by 285
Clinical significance of Janus Kinase inhibitor selectivity
Choy, E. H. (2019) · Rheumatology · doi:10.1093/rheumatology/key339 · Cited by 285
Smitten, A. L., Choi, H. K., Hochberg, M. C., Suissa, S., Simon, T. A., Testa, M. A., & Chan, K. A. (2007) · Arthritis Care & Research · doi:10.1002/art.23112 · Cited by 281
Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206478 · Cited by 281
Papp, K. A., Menter, M. A., Raman, M., Disch, D., Schlichting, D. E., Gaich, C., Macias, W., Zhang, X., & Janes, J. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14403 · Cited by 263
van der Heijde, D., Baraliakos, X., Gensler, L. S., Maksymowych, W. P., Tseluyko, V., Nadashkevich, O., Abi-Saab, W., Tasset, C., Meuleners, L., Besuyen, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32463-2 · Cited by 242
Westhovens, R., Taylor, P. C., Alten, R., Pavlova, D., Enríquez-Sosa, F., Mazur, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210104 · Cited by 236
Kavanaugh, A., Kremer, J., Ponce, L., Cseuz, R., Reshetko, O. V., Stanislavchuk, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210105 · Cited by 229
Winthrop, K. L., Baddley, J. W., Chen, L., Liu, L., Grijalva, C. G., Delzell, E., Beukelman, T., Patkar, N. M., Xie, F., Saag, K. G., et al. (2013) · JAMA · doi:10.1001/jama.2013.1099 · Cited by 223
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Winthrop, K. L., Melmed, G. Y., Vermeire, S., Long, M. D., Chan, G., Pedersen, R. D., Lawendy, N., Thorpe, A. J., Nduaka, C. I., & Su, C. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy131 · Cited by 213
Ports, W. C., Khan, S., Lan, S., Lamba, M., Bolduc, C., Bissonnette, R., & Papp, K. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12266 · Cited by 204
Genovese, M. C., Smolen, J. S., Weinblatt, M. E., Burmester, G. R., Meerwein, S., Camp, H. S., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39808 · Cited by 200
Incidence of herpes zoster in patients with altered immune function
Chen, S.-Y., Suaya, J. A., Li, Q., Galindo, C. M., Misurski, D., Burstin, S., & Levin, M. J. (2014) · Infection · doi:10.1007/s15010-013-0550-8 · Cited by 198
Mease, P., Coates, L. C., Helliwell, P. S., Stanislavchuk, M., Rychlewska-Hanczewska, A., Dudek, A., Abi-Saab, W., Tasset, C., Meuleners, L., Harrison, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32483-8 · Cited by 196
Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease
Long, M. D., Martin, C., Sandler, R. S., & Kappelman, M. D. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12182 · Cited by 186
Kremer, J. M., Emery, P., Camp, H. S., Friedman, A., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., Jungerwirth, S., & Keystone, E. C. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39801 · Cited by 182
Danese, S., Grisham, M., Hodge, J., & Telliez, J.-B. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00311.2015 · Cited by 180
Self-citationXie, W., Huang, Y., Xiao, S., Sun, X., Fan, Y., & Zhang, Z. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214846 · Cited by 168
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
Sandborn, W. J., Panés, J., Sands, B. E., Reinisch, W., Su, C., Lawendy, N., Koram, N., Fan, H., Jones, T. V., Modesto, I., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15514 · Cited by 168
Self-citationPapp, K. A., Krueger, J. G., Feldman, S. R., Langley, R. G. B., Thaçi, D., Torii, H., Tyring, S. K., Wolk, R. A., Gardner, A., Mebus, C., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.01.013 · Cited by 157
Souto, A., Maneiro, J. R., Salgado, E., Carmona, L., & Gómez-Reino, J. J. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/keu172 · Cited by 155
Yamanaka, H., Tanaka, Y., Takeuchi, T., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0932-2 · Cited by 154
Next generation of small molecules in inflammatory bowel disease
Olivera, P., Danese, S., & Peyrin-Biroulet, L. (2017) · Gut · doi:10.1136/gutjnl-2016-312912 · Cited by 154
Self-citationBissonnette, R., Iversen, L., Sofen, H. L., Griffiths, C. E. M., Foley, P. A., Romiti, R., Bachinsky, M., Rottinghaus, S. T., Tan, H., Proulx, J., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13551 · Cited by 151
Charles‐Schoeman, C., Wicker, P. A., González-Gay, M. Á., Boy, M. G., Zuckerman, A. L., Soma, K., Geier, J. L., Kwok, K. K., & Riese, R. J. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.05.014 · Cited by 151
Tanaka, Y., Takeuchi, T., Yamanaka, H., Nakamura, H., Toyoizumi, S., & Zwillich, S. H. (2014) · Modern Rheumatology · doi:10.3109/14397595.2014.995875 · Cited by 135
Marra, F., Lo, E. A., Kalashnikov, V., & Richardson, K. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw205 · Cited by 128
McInnes, I. B., Kim, H., Lee, S., Mandel, D. R., Song, Y.-W., Connell, C. A., Luo, Z., Brosnan, M. J., Zuckerman, A. L., Zwillich, S. H., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202442 · Cited by 127
Tanaka, Y., Emoto, K., Cai, Z., Aoki, T., Schlichting, D. E., Rooney, T. P., & Macias, W. L. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150613 · Cited by 124
Mohamed, M. F., Camp, H. S., Jiang, P. X., Padley, R. J., Asatryan, A., & Othman, A. A. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0419-y · Cited by 119
Colombel, J. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy150 · Cited by 119
Desai, R. J., Pawar, A. M., Weinblatt, M. E., & Kim, S. C. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40798 · Cited by 117
Ravelli, A., Minoia, F., Davì, S., Horne, A., Bovis, F., Pistorio, A., Aricò, M., Avčin, T., Behrens, E. M., Benedetti, F. D., et al. (2016) · RMD Open · doi:10.1136/rmdopen-2015-000161 · Cited by 96
JAK inhibition in inflammatory bowel disease
Olivera, P. A., Danese, S., & Peyrin‐Biroulet, L. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1291342 · Cited by 94
Self-citationZhang, J., Tsai, T., Lee, M., Zheng, M., Wang, G., Jin, H., Gu, J., Li, R.-Y., Liu, Q., Jin, C., et al. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.05.004 · Cited by 90
Curtis, J. R., Xie, F., Yang, S., Bernatsky, S., Chen, L., Yun, H., & Winthrop, K. L. (2018) · Arthritis Care & Research · doi:10.1002/acr.23769 · Cited by 87
Asahina, A., Etoh, T., Igarashi, A., Imafuku, S., Saeki, H., Shibasaki, Y., Tomochika, Y., Toyoizumi, S., Nagaoka, M., Ohtsuki, M., et al. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13258 · Cited by 85
Sandborn, W. J., Feagan, B. G., Panés, J., D’Haens, G., Colombel, J., Zhou, Q., Huang, B., Enejosa, J., Pangan, A. L., & Lacerda, A. P. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)34357-3 · Cited by 85
Vanhoutte, F. P., Mazur, M., Voloshyn, O. I., Stanislavchuk, M., der Aa, A. V., Namour, F., Galien, R., Meuleners, L., & Klooster, G. A. E. V. '. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40186 · Cited by 83
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Cohen, S. B., Curtis, J. R., DeMasi, R., Chen, Y., Fan, H., Soonasra, A., & Fleischmann, R. (2018) · Rheumatology and Therapy · doi:10.1007/s40744-018-0097-3 · Cited by 81
Keystone, E. C., Genovese, M. C., Schlichting, D. E., de la Torre, I., Beattie, S. D., Rooney, T. P., & Taylor, P. C. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161161 · Cited by 69
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Machado, M. A. D. Á., de Moura, C. S., Guerra, S. F., Curtis, J. R., Abrahamowicz, M., & Bernatsky, S. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1539-6 · Cited by 69
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Genovese, M. C., Kremer, J. M., Kartman, C. E., Schlichting, D. E., Xie, L., Carmack, T., Pantojas, C., Bursón, J. S., Tony, H., Macias, W. L., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/kex489 · Cited by 65
Cohen, S. B., Zwillich, S. H., Chow, V., LaBadie, R. R., & Wilkinson, B. E. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03570.x · Cited by 59
Kremer, J. M., Kivitz, A., Campos, J. A. S., Nasonov, E. L., Tony, H., Lee, S.-K., Vlahos, B. L., Hammond, C., Bukowski, J. F., Li, H., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0612-7 · Cited by 55
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis
Allen, P. B., Olivera, P. A., Emery, P., Moulin, D., Jouzeau, J., Netter, P., Danese, S., Feagan, B. G., Sandborn, W. J., & Peyrin‐Biroulet, L. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13995 · Cited by 48
Self-citationWu, J. J., Strober, B. E., Hansen, P. R., Ahlehoff, O., Egeberg, A., Qureshi, A. A., Robertson, D. H., Valdez, H., Tan, H., & Wolk, R. A. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.06.012 · Cited by 45
Tanaka, Y., Ishii, T., Cai, Z., Schlichting, D. E., Rooney, T. P., & Macias, W. L. (2017) · Modern Rheumatology · doi:10.1080/14397595.2017.1307899 · Cited by 41
Troncone, E., Marafini, I., Blanco, G. D. V., Grazia, A. D., & Monteleone, G. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s208020 · Cited by 33
Fleischmann, R., Takeuchi, T., Schiff, M. H., Schlichting, D. E., Xie, L., Issa, M., Stoykov, I., LISSE, J. R., Martínez-Osuna, P., Rooney, T. P., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.24007 · Cited by 32
Fleischmann, R., Huizinga, T. W. J., Kavanaugh, A. F., et al. (2016) · RMD Open · doi:10.1136/rmdopen-2016-000262 · Cited by 31
Tanaka, Y., Fautrel, B., Keystone, E. C., Ortmann, R., Xie, L., Zhu, B., Issa, M., Patel, H. J., Gaich, C. L., de Bono, S., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214529 · Cited by 25
Panés, J., Sandborn, W. J., Loftus, E. V., Assche, G. V., Ghosh, S. K., Zhou, Q., Goteti, S., Enejosa, J., Pangan, A. L., & Lacerda, A. P. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx180.400 · Cited by 20
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Raine, T., Bonovas, S., Burisch, J., Kucharzik, T., Adamina, M., Annese, V., Bachmann, O., Bettenworth, D., Chaparro, M., Czuber-Dochan, W., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab178 · Cited by 1,100
Self-citationUlcerative Colitis in Adults: A Review
Gros, B., & Kaplan, G. G. (2023) · JAMA · doi:10.1001/jama.2023.15389 · Cited by 738
Kucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
Lasa, J. S., Olivera, P. A., Danese, S., & Peyrin-Biroulet, L. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00377-0 · Cited by 384
Self-citation
Metadata
- Authors
- Olivera, P. A., Lasa, J. S., Bonovas, S., Danese, S., & Peyrin-Biroulet, L.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 158
- Issue
- 6
- Pages
- 1554-1573.e12
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W3000133404
- Cited by
- 330
- References
- 90
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.